Plausibly Alleging Non-monetary Settlements as Reverse Payments After Actavis

Published date25 March 2015
Law FirmPatterson Belknap Webb & Tyler LLP
AuthorGeorge LoBiondo,Deirdre McEvoy
Subject MatterAntitrust Litigation,FTC v Actavis,Generic Drugs,Lipitor,Patent Infringement,Pharmaceutical Manufacturers,Pharmaceutical Patents,Pleading Standards,Reverse Payment Settlement Agreements,Twombly/Iqbal Pleading Standard

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT